Laser aggregometer studies, ATP release and thromboxane B2 release and cAMP concentration of the platelets in nephrotic syndrome.
Platelet function was studied in 56 children with nephrotic syndrome, 33 were on oral prednisolone (P) treatment (group 1), while 23 were in early (< 6 months) remission (group 2): 12 on P (group 2a) and 11 not on P (group 2b), and there were 18 controls (group 3). The following tests were used: platelet aggregation with collagen in a laser rheoaggregometer; adenosine triphosphate (ATP) release: during aggregation with luciferin-luciferase in a lumiaggregometer; thromboxane B2 (TXB2) release: by radioimmunoassay; platelet cAMP concentration: by binding assay. The changes in plasma cholesterol (C) and triglycerides (TG) were compared with the platelet aggregation results. Patients in group 1 and 2 exhibited significantly higher aggregability, TXB2 release and ATP release in response to collagen than those in group 3 (p < 0.01), but there was no difference between groups 1 and 2 or groups 2a and 2b. Some differences were observed between the histological groups. Patients with IgA and SLE nephropathy displayed higher aggregability than those with minimal change nephrotic syndrome in remission (p < 0.05). The highest level was in membranous nephropathy. The platelet cyclic adenosine monophosphate (cAMP) concentration was significantly lower in groups 1 and 2 than in group 3 (p < 0.001). No differences were observed between groups 1 and 2 or between groups 2a and 2b. Plasma C and TG levels did not show any correlation with the platelet aggregation.(ABSTRACT TRUNCATED AT 250 WORDS)
Turi
S
S
Department of Paediatrics, Albert Szent-Gyorgyi Medical University, Szeged, Hungary.
Bereczki
C
C
Torday
C
C
Havass
Z
Z
D000255:Adenosine Triphosphate / Q000378:metabolism; D000293:Adolescent; D001792:Blood Platelets / Q000502:physiology*; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D000242:Cyclic AMP / Q000097:blood; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009404:Nephrotic Syndrome / Q000097:blood* / Q000188:drug therapy; D010974:Platelet Aggregation; D011239:Prednisolone / Q000627:therapeutic use; D013929:Thromboxane B2 / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D014280:Triglycerides; D013929:Thromboxane B2; D000255:Adenosine Triphosphate; D002784:Cholesterol; D011239:Prednisolone; D000242:Cyclic AMP